CollabNet VersionOne and XebiaLabs Combine to Create Integrated Agile DevOps Platform
22.1.2020 05:10:00 EET | Business Wire | Press release
CollabNet VersionOne (CollabNet), a leading provider for Agile planning and collaborative development, and XebiaLabs, the leader in release orchestration, deployment, and continuous delivery, announced today that the two companies have merged. The combination, which was backed by TPG Capital, unites CollabNet’s upstream Agile planning and enterprise version control functionality with XebiaLabs’ downstream release orchestration and deployment automation capabilities to create an Agile, end-to-end, DevOps platform for enterprises.
In connection with the transaction, Ashok Reddy, an accomplished industry veteran and former Broadcom executive, has joined the combined company as CEO. He replaces Flint Brenton, who is stepping aside to focus on family and personal interests after nearly five years of successful stewardship. Derek Langone, current CEO of XebiaLabs, will serve as President of the combined company. Stephen Gregorio, EVP and CFO of XebiaLabs, will serve as the combined company’s CFO.
“The combination of CollabNet and XebiaLabs will provide enterprise customers with the end-to-end visibility and management capabilities needed to develop software quickly, reliably, and securely, ultimately helping accelerate their digital transformation and drive business outcomes,” said Nehal Raj and Art Heidrich of TPG Capital. “We congratulate Flint on a successful tenure, and look forward to partnering with Ashok, Derek, and the broader team to further accelerate our strategy to create a leading enterprise DevOps platform company.”
Founded in 2008, XebiaLabs is a high-growth provider of release management and automation developer tools. The company provides release orchestration and application delivery software that enables enterprises to orchestrate, automate, and analyze the entire software release pipeline at enterprise scale. XebiaLabs’ downstream capabilities complement CollabNet’s upstream product portfolio, which includes VersionOne for enterprise Agile planning and management, VS for connected workflows and visibility throughout the entire delivery value stream, and TeamForge for enterprise-scale version control management and application lifecycle management. Both companies’ platforms and tools are recognized by analysts as industry-leading offerings that drive innovation into the market.
“We are on a mission to fundamentally transform how enterprise software development and delivery is done,” said Reddy. “The combination of CollabNet and XebiaLabs will provide a platform that enables digital transformation at scale with Agile and DevOps processes to continuously adapt, learn, and improve, especially in a world of AI-driven intelligent apps and experiences. I am thrilled to be joining at this critical juncture and look forward to working with the entire team to lead the combined company through its next chapter of growth.”
“XebiaLabs has established itself as the standard for DevOps in large enterprises. Counting among our clients the world’s largest financial, healthcare, and manufacturing companies, our focus has been on creating a platform that takes advantage of existing tooling and processes while providing the scale, standardization, security, and reporting that large companies require,” said Langone. “I am thankful for what we have been able to achieve with the support of Susquehanna Growth Equity and Accel. By combining XebiaLabs and CollabNet, our mutual clients will now benefit from the most capable Agile DevOps platform available in the market. This is a game changer for businesses that need to maximize their software application assets while navigating complex regulatory, compliance, and security requirements.”
Most recently, Reddy led Broadcom’s multibillion-dollar Enterprise Software Division, where he helped create a platform for global enterprises to scale their digital transformations and become real-time digital businesses. With a career spanning more than 25 years in enterprise software and deep experience in Agile and DevOps transformation, Reddy has held leadership positions at several Fortune 500 companies including IBM, CA Technologies, Rational Software, Honeywell, and Novartis. Reddy will work closely with Langone and Gregorio, both experienced software executives, to lead the combined company.
“I thank my colleagues at CollabNet for the success created by their hard work and dedication,” said Brenton. “While I am proud of all we have built together, I have decided it is the right time for me to return to California and begin the next chapter of my life. CollabNet and XebiaLabs are in strong and capable hands with Ashok, Derek, and TPG Capital, and I am confident that under their leadership, the combined company will achieve even greater success and scale.”
Barclays, Evercore, and KeyBanc served as financial advisors to TPG Capital and CollabNet, and Ropes & Gray LLP served as legal counsel. Shea & Company served as financial advisor to XebiaLabs, and Weil, Gotshal & Manges LLP served as legal counsel. XebiaLabs’ existing shareholders, Susquehanna Growth Equity and Accel, have sold their respective stakes in the company as part of the combination. Additional terms of the transaction were not disclosed.
About CollabNet VersionOne
CollabNet VersionOne is a leading platform provider for Value Stream Management, Agile planning, DevOps and source code management. Its offerings provide global enterprise and government industry leaders a cohesive solution that enables them to ideate, create and orchestrate the flow of value through continuous delivery pipelines with measurable business outcomes. To learn more visit: www.collab.net
About XebiaLabs
XebiaLabs' mission is to help large companies accelerate their software releases with more reliability - no matter how diverse the infrastructure or complex the processes. The XebiaLabs DevOps Platform is the industry's only end-to-end DevOps toolchain orchestration and reporting solution, providing the automation, control, and visibility enterprises need to deliver software faster and with less risk. With the XebiaLabs DevOps Platform, organizations can connect all their DevOps tools, manage their interactions, deploy to any environment, and create a data hub for reporting, without ad-hoc scripting and endless maintenance. For more information, please visit www.xebialabs.com.
About TPG
TPG is a leading global alternative asset firm founded in 1992 with more than $119 billion of assets under management and offices in Austin, Beijing, Boston, Dallas, Fort Worth, Hong Kong, Houston, London, Luxembourg, Melbourne, Moscow, Mumbai, New York, San Francisco, Seoul, and Singapore. TPG's investment platforms are across a wide range of asset classes, including private equity, growth equity, real estate, credit, and public equity. TPG aims to build dynamic products and options for its investors while also instituting discipline and operational excellence across the investment strategy and performance of its portfolio. For more information, visit www.tpg.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200121006172/en/
Contact information
Media
Olivia Heel, Catapult PR-IR
oheel@catapultpr-ir.com
303-581-7760
Hannah Inman
press@xebialabs.com
TPG
Luke Barrett and Courtney Power
media@tpg.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom